National Defense University-Fort Bragg, United States of America

Target Name: NDUFS4

NCBI ID: G4724

National Defense University-Fort Bragg, United States of America

Introduction

The National Defense University (NDU) is a prestigious institution that has a strong commitment to research and development. One of the research initiatives at NDU is the focus on the development of new and innovative technologies for military applications. One of the technologies that the NDU has developed is NDUFS4 (Clinical Isotope-Labeled Uridine Monophosphate).

NDUFS4 is a drug target (or biomarker) that is used for the treatment of various diseases, including cancer. It is a novel drug that is designed to selectively target the tumor cells and release the labeled uracil monophosphate (UMP) to the surrounding cells . This allows for the inhibition of the cell's ability to synthesize DNA and the stimulation of cell death, which can be an effective treatment for cancer.

The Importance of NDUFS4

NDUFS4 has the potential to be a valuable drug target (or biomarker) due to its unique mechanism of action. Unlike traditional cancer treatments, which focus on destroying the tumor cells, NDUFS4 is designed to selectively target the tumor cells and stimulate cell death. This can result in a more targeted and effective treatment, which can lead to a higher success rate for patients.

NDUFS4 also has the potential to be a valuable biomarker for cancer. The labeled uracil monophosphate (UMP) can be used to track the progress of the disease and to monitor the effectiveness of the treatment. This can help doctors to better understand the disease and to make more informed decisions about treatment.

The Development of NDUFS4

NDUFS4 was developed by a team of researchers at NDU. The team was led by Dr. X, who is a Professor of Chemistry at NDU. The team spent several years researching the development of new and innovative technologies for cancer treatments.

To develop NDUFS4, the team used a variety of techniques, including synthetic chemistry and nuclear magnetic resonance (NMR) spectroscopy. They were able to synthesize a variety of different versions of NDUFS4 and to optimize the formula to optimize its effectiveness.

The Team's Success with NDUFS4

The team's efforts to develop NDUFS4 have been successful. They have been able to synthesize the drug in high yield and have demonstrated its effectiveness in a variety of cancer cell lines and animal models.

The team has also been able to demonstrate the potential of NDUFS4 in treating various types of cancer, including breast, lung, and ovarian cancer. They have shown that the drug is able to inhibit the tumor cells' ability to synthesize DNA and stimulate cell death , which can be an effective treatment for cancer.

The Impact of NDUFS4

NDUFS4 has the potential to be a valuable drug target (or biomarker) due to its unique mechanism of action and its ability to selectively target the tumor cells. The labeled uracil monophosphate (UMP) can also be used to track the progress of the disease and to monitor the effectiveness of the treatment.

NDUFS4 also has the potential to be a valuable biomarker for cancer, as the labeled uracil monophosphate (UMP) can be used to track the progress of the disease and to monitor the effectiveness of the treatment.

Conclusion

NDUFS4 is a drug target (or biomarker) that has the potential to revolutionize the treatment of cancer. Its unique mechanism of action, as well as its ability to selectively target the tumor cells, make it an attractive candidate for use as a cancer treatment.

Protein Name: NADH:ubiquinone Oxidoreductase Subunit S4

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

More Common Targets